


BMP agonist 1

Cat. No.:	HY-155705
Molecular Formula:	C ₂₁ H ₁₆ N ₂ O ₆
Molecular Weight:	392.36
Target:	TGF-β Receptor; GSK-3; β-catenin
Pathway:	TGF-beta/Smad; PI3K/Akt/mTOR; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BMP agonist 1 (compound 2 b) is a small-molecule agonist of bone morphogenic protein (BMP). BMP induces C2C12 cell differentiation with BMP and highly depends on active BMP signaling. BMP agonist 1 inhibits GSK3β, increases β-catenin signaling and synergistically regulates Id2 and Id3 expression. BMP agonist 1 is used in diseases and defects of the skeleton research ^[1] .																
In Vitro	<p>BMP agonist 1 (0.01-10 μM, 24 h) reduces the proliferation of C2C12 cells^[1].</p> <p>BMP agonist 1 (0.5-1 μM, 2 h) inhibits GSK3β, increases β-catenin signaling and synergistically regulates Id2 and Id3 expression in C2C12 cells^[1].</p> <p>BMP agonist 1 (0.01-10 μM) potently promotes the osteogenic differentiation (Alp activity) of the canonical BMP potentiator Chromenone 1 (HY-143891) in C2C12 cells when in combination with Chromenone 1 (0.5-1 μM)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>C2C12 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.01-10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24, 72 h</td> </tr> <tr> <td>Result:</td> <td>Differentiated in C2C12 osteoblast at the low-dose BMP-4 (7.5 ng/mL). Reduced the cell numbers and stopped the proliferation at higher concentrations. Highly induced Id1 and Id3, elevated Runx2 levels.</td> </tr> </table> <p>Cell Differentiation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>C2C12 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.01-10 μM (in combination with (0.05, 0.2, 0.5, or 1 μM Chromenone 1)</td> </tr> <tr> <td>Incubation Time:</td> <td></td> </tr> <tr> <td>Result:</td> <td>Highly overadditive effects and increased potency with Chromenone 1. Reached the highest synergy scores (i.e., delta scores) at a concentration of 0.3 μM with 0.5-1 μM Chromenone 1.</td> </tr> </table>	Cell Line:	C2C12 cells	Concentration:	0.01-10 μM	Incubation Time:	24, 72 h	Result:	Differentiated in C2C12 osteoblast at the low-dose BMP-4 (7.5 ng/mL). Reduced the cell numbers and stopped the proliferation at higher concentrations. Highly induced Id1 and Id3, elevated Runx2 levels.	Cell Line:	C2C12 cells	Concentration:	0.01-10 μM (in combination with (0.05, 0.2, 0.5, or 1 μM Chromenone 1)	Incubation Time:		Result:	Highly overadditive effects and increased potency with Chromenone 1. Reached the highest synergy scores (i.e., delta scores) at a concentration of 0.3 μM with 0.5-1 μM Chromenone 1.
Cell Line:	C2C12 cells																
Concentration:	0.01-10 μM																
Incubation Time:	24, 72 h																
Result:	Differentiated in C2C12 osteoblast at the low-dose BMP-4 (7.5 ng/mL). Reduced the cell numbers and stopped the proliferation at higher concentrations. Highly induced Id1 and Id3, elevated Runx2 levels.																
Cell Line:	C2C12 cells																
Concentration:	0.01-10 μM (in combination with (0.05, 0.2, 0.5, or 1 μM Chromenone 1)																
Incubation Time:																	
Result:	Highly overadditive effects and increased potency with Chromenone 1. Reached the highest synergy scores (i.e., delta scores) at a concentration of 0.3 μM with 0.5-1 μM Chromenone 1.																

REFERENCES

[1]. Riege D, et al. Identification of Maleimide-Fused Carbazoles as Novel Noncanonical Bone Morphogenetic Protein Synergizers. ACS Pharmacol Transl Sci. 2023 Jul 19;6(8):1207-1220.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA